| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Benefits and Risks of Non-Approved Injection Regimens for Botulinum Toxins in Spasticity
|
Santamato, Andrea
|
|
2017
|
77 |
13 |
p. 1413-1422
|
artikel
|
| 2 |
Delafloxacin: First Global Approval
|
Markham, Anthony
|
|
2017
|
77 |
13 |
p. 1481-1486
|
artikel
|
| 3 |
Delafloxacin: First Global Approval
|
Markham, Anthony
|
|
2018
|
77 |
13 |
p. 1481-1486
|
artikel
|
| 4 |
Factors Contributing to the Efficacy-Effectiveness Gap in the Case of Orphan Drugs for Metabolic Diseases
|
Schuller, Y.
|
|
2017
|
77 |
13 |
p. 1461-1472
|
artikel
|
| 5 |
Guselkumab: First Global Approval
|
Markham, Anthony
|
|
2017
|
77 |
13 |
p. 1487-1492
|
artikel
|
| 6 |
Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects
|
Poulakou, Garyphallia
|
|
2017
|
77 |
13 |
p. 1399-1412
|
artikel
|
| 7 |
Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects
|
Poulakou, Garyphallia
|
|
|
77 |
13 |
p. 1399-1412
|
artikel
|
| 8 |
Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT
|
Syed, Yahiya Y.
|
|
2017
|
77 |
13 |
p. 1473-1480
|
artikel
|
| 9 |
Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?
|
Bannwarth, Bernard
|
|
2017
|
77 |
13 |
p. 1377-1387
|
artikel
|
| 10 |
Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook
|
Ahluwalia, Jusleen
|
|
2017
|
77 |
13 |
p. 1389-1397
|
artikel
|
| 11 |
Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review
|
Veerman, Selene R. T.
|
|
2017
|
77 |
13 |
p. 1423-1459
|
artikel
|
Tijdschrift beschrijving